Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
KIT D579del Imatinib thymic carcinoma sensitive detail...
KIT Y553N Imatinib thymic carcinoma sensitive detail...
KIT V560del KIT over exp Imatinib thymic carcinoma sensitive detail...
KIT P577_D579del Sorafenib thymic carcinoma sensitive detail...
KIT D820E Sorafenib thymic carcinoma sensitive detail...
Unknown unknown Selinexor thymic carcinoma not applicable detail...
Unknown unknown Bevacizumab + MINT1526A thymic carcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01011439 Phase II Milciclib Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Terminated
NCT01025089 Phase II Cetuximab Cisplatin + Doxorubicin + Cyclophosphamide Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma Active, not recruiting
NCT01301391 Phase II Milciclib Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy Terminated
NCT01396408 Phase II Temsirolimus Sunitinib A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours Active, not recruiting
NCT01621568 Phase II Sunitinib Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Active, not recruiting
NCT02364076 Phase II Pembrolizumab MK-3475 in Patients With Thymic Carcinoma Active, not recruiting
NCT03076554 Phase II Avelumab A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting
NCT03193437 Phase II Selinexor Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy Recruiting
NCT03295227 Phase I Pembrolizumab Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma Recruiting
NCT03463460 Phase II Pembrolizumab + Sunitinib Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer Suspended
NCT03583086 Phase Ib/II Nivolumab + Vorolanib H I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors Recruiting
NCT03694002 Phase II Paclitaxel + Carboplatin Ramucirumab + Paclitaxel + Carboplatin Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery Recruiting